>

Julian Adams - CLAL BIOTECHNOLOGY President Chief Scientific Officer

<div class='circular--portrait' style='background:#FF9E01;color: white;font-size:3em;padding-top: 40px;;'>CLA</div>
  President
Dr. Julian Adams was appointed President and Chief Scientific Officer at Clal Biotechnology Industries Ltd effective January 23, 2017. He is a scientist. He has developed new molecules that impact human disease, developed the drug Viramune for HIV and is active within the medical innovation and cancer research. Dr. Adams work experience includes the following roles Director of Medicinal Chemistry at Boehringer Ingelheim, Senior Vice President of drug discovery and development at Millennium Pharmaceuticals, President of Research and Development at Infinity Pharmaceuticals, Inc. and Advisor to the American Association for Cancer Research and other cancerrelated foundations. He holds more than 40 patents and has authored more than 100 papers and book chapters in peerreviewed journals and has received many awards
Age: 62  President Since 2017      
972 3 612 1616  http://www.cbi.co.il
Adams holds a BS degree and a Doctorate of Science degree from McGill University and a PhD degree in Synthetic Organic Chemistry from Massachusetts Institute of Technology.

Management Efficiency

The company has return on total asset (ROA) of (5.15) % which means that it has lost $5.15 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (1.79) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 52.28 M in total debt with debt to equity ratio (D/E) of 6.3 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. CLAL BIOTECHNOLOGY has Current Ratio of 3.6 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Showing few of many executives

PRESIDENT Since

Lilach HarelICL ISRAEL CHEM
2019
Ronnie ShushanICL ISRAEL CHEM
2014
Anat TalKtalavICL ISRAEL CHEM
2018
Osi SesslerICL ISRAEL CHEM
2008
Eli GlazerICL ISRAEL CHEM
2018
Eli AmitICL ISRAEL CHEM
2002
Rani LoebensteinICL ISRAEL CHEM
2017
Karl MielkeICL ISRAEL CHEM
2013
Lizette KillianICL ISRAEL CHEM
2015
Amir BenitaICL ISRAEL CHEM
2012
Ofer LifshitzICL ISRAEL CHEM
2018
Michael HazzanICL ISRAEL CHEM
2012
Herzel NivICL ISRAEL CHEM
2008
Hezi IsraelICL ISRAEL CHEM
2012
Yakir MenasheICL ISRAEL CHEM
2013
Kobi AltmanICL ISRAEL CHEM
2015
Ilana FahimaICL ISRAEL CHEM
2018
Ido LilianICL ISRAEL CHEM
2014

Company Summary

Clal Biotechnology Industries Ltd. is a private equity and venture capital firm specializing in development stage, pre-clinical incubation, seed, start-up, early venture, emerging growth, mid venture, late venture, PIPEs, and growth capital stages of financing. It operates as a subsidiary of Clal Industries and Investments Ltd. CLAL BIOTECHNOLOGY operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange.CLAL BIOTECHNOLOGY (CBI) is traded on Tel Aviv Stock Exchange in Israel and employs 14 people.

CLAL BIOTECHNOLOGY Leadership Team

Ofer Goldberg, VPView
Sigalia Heifetz, DirectorView
Shmuel Rubinstein, External DirectorView
Tomer Babai, DirectorView
Dafna Gruber, DirectorView
Aharon Schwartz, DirectorView
Gavriel Barabash, DirectorView
Isaac Kohlberg, DirectorView
Nofar Malovani, DirectorView
Assaf Segal, CFOView
Ofer Gonen, Vice PresidentView
Avraham Fischer, Chairman of the BoardView
Yuval Yanai, External DirectorView
Julian Adams, President Chief Scientific OfficerView
Orit Lidor, VP and General CounselView

Stock Performance Indicators

Current Sentiment - CBI

CLAL BIOTECHNOLOGY Investor Sentiment

Most of Macroaxis users are currently bullish on CLAL BIOTECHNOLOGY. What is your opinion about investing in CLAL BIOTECHNOLOGY? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

CLAL BIOTECHNOLOGY Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Intel and Diodes Incorporated. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check out Trending Equities. Please also try Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.